Comparative Pharmacology
Head-to-head clinical analysis: ILUVIEN versus ORAPRED ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILUVIEN versus ORAPRED ODT.
ILUVIEN vs ORAPRED ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory and immunosuppressive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
10-60 mg orally once daily or divided twice daily; maximum 60 mg/day.
None Documented
None Documented
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
Terminal elimination half-life: 2-3 hours (after IV/IM/oral). Clinically, anti-inflammatory effects persist beyond plasma half-life due to glucocorticoid receptor-mediated gene transcription effects.
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Primarily renal (80-90% as inactive glucuronide and sulfate conjugates; less than 10% as unchanged drug). Biliary/fecal excretion accounts for about 5%.
Category C
Category C
Corticosteroid
Corticosteroid